...http://www.tescoplc.com/files/pdf/reports/ar15/download_annual_report.pdf http://www.tescoplc.com/files/pdf/reports/ar15/download_annual_report.pdf http://www.tescoplc.com/files/pdf/reports/ar15/download_annual_report.pdf http://www.tescoplc.com/files/pdf/reports/ar15/download_annual_report.pdf http://www.tescoplc.com/files/pdf/reports/ar15/download_annual_report.pdf http://www.tescoplc.com/files/pdf/reports/ar15/download_annual_report.pdf http://www.tescoplc.com/files/pdf/reports/ar15/download_annual_report.pdf http://www.tescoplc.com/files/pdf/reports/ar15/download_annual_report.pdf http://www.tescoplc.com/files/pdf/reports/ar15/download_annual_report.pdf http://www.tescoplc.com/files/pdf/reports/ar15/download_annual_report.pdf http://www.tescoplc.com/files/pdf/reports/ar15/download_annual_report.pdf http://www.tescoplc.com/files/pdf/reports/ar15/download_annual_report.pdf http://www.tescoplc.com/files/pdf/reports/ar15/download_annual_report.pdf http://www.tescoplc.com/files/pdf/reports/ar15/download_annual_report.pdf http://www.tescoplc.com/files/pdf/reports/ar15/download_annual_report.pdf http://www.tescoplc.com/files/pdf/reports/ar15/download_annual_report.pdf http://www.tescoplc.com/files/pdf/reports/ar15/download_annual_report.pdf http://www.tescoplc.com/files/pdf/reports/ar15/download_annual_report.pdf http://www.tescoplc.com/files/pdf/reports/ar15/download_annual_report.pdf http://www.tescoplc.com/files/pdf/reports/ar15/download_annual_report.pdf http://www...
Words: 831 - Pages: 4
...Brochure More information from http://www.researchandmarkets.com/reports/2892292/ Hodgkin Lymphoma - Pipeline Review, H2 2014 Description: Hodgkin Lymphoma - Pipeline Review, H2 2014 Summary This, ‘Hodgkin Lymphoma - Pipeline Review, H2 2014’, provides an overview of the Hodgkin Lymphoma’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hodgkin Lymphoma and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box...
Words: 2420 - Pages: 10
...0 0 REPORT OF THE COMMITTEE ON 0 0 THE F INANCIAL A S P E C T S OF C ORPORATE G OVERNANCE 1 DE C E M B E R 1992 0 0 REPORT OF THE COMMITTEE ON 0 0 THE F INANCIAL A S P E C T S OF C ORPORATE G OVERNANCE 0 1992 The Committee on the Financial Aspects of Corporate Governance and Gee and Co. Ltd. Reproduction of this publication in whole or in part is unrestricted for internal communications within a given organisation. It is otherwise subject to permission which will not be refused but will attract a reasonable reproduction charge. A leaflet is available from the Publishers setting out full details of the level of the charge and when it is applicable. First published December 1992 ISBN 0 85258 913 1 (Report) ISBN 0 85258 915 8 (Report with Code of Best Practice) Gee (a division of Professional Publishing Ltd) South Quay Plaza 183 Marsh Wall London El4 9FS Freephone: (0800) 289520 Fax: (071) 537-2557 Printed in Great Britain by Burgess Science Press. Queries and correspondence relating to the report should be addressed to: The Secretary Committee on the Financial Aspects of Corporate Governance Up to 31 Decemher~ 1992 P.O. Box 433 Moorgate Place London EC2P 2BJ Tel: (07 I) 628-7060 ext.2565 Fax: (071) 6281874 From 1 Ja/rrrar~y 1 9 9 3 c/o The London Stock Exchange L o n d o n EC2N IHP Tel: (071) 797-4575 Fax: (071) 4.1~0:6822 Additional copies of the report may be obtained from: Gee (a division...
Words: 26162 - Pages: 105
...2/16/2014 Intellectual Property creation witnessing steady growth in India: Report - Economic Times You are here: Home > Collections > India RELATED ARTICLES Budget 2012: Relax corporate tax and surcharges to boost... March 5, 2012 Intellectual Property creation witnessing steady growth in India: Report PTI Jun 26, 2013, 06.43PM IST Bharti Airtel gives IP contract to Alcatel Lucent India June 1, 2012 Tags: Texas Instruments general motors | Mercedes-Benz | investments | intellectual property | Intel | Hewlett-Packard | | gdp | Alstom | Alcatel Lucent Alcatel-Lucent launches IP Transformation Center Septemb er 8, 2009 IN-DEPTH COVERAGE India Intellectual Property Alcatel-lucent Alstom NEW DELHI: The country's contribution to Intellectual Property (IP) creation is witnessing a steady growth, however, investments in R&D and patent activities in the country are still relatively slow when compared to developed nations, a report says. According to globalisation and market expansion advisory firm Zinnov's study 'Enhancing the IP Quotient in MNC R&D centres', IP creation is witnessing steady growth in MNC R&D centres, but investments in R&D and patent activities in India are still relatively slow. (A sector-wise analysis…) The study further said India spends just 1 per cent of its GDP on R&D, while countries like Israel spends 4.2 per cent, Japan 3.7 per cent, US 2.7 per cent and China 2.0 per cent...
Words: 815 - Pages: 4
... I understand the college policy on plagiarism. Student signature showing understanding of plagiarism notice To be filled by Lecturer Guidelines: 1) R: Referred P: Pass M: Merit D: Distinction 2) Feedback: Please put comments depending upon grade, for example if R- what can be improved and if P – you could give positive feedback. Circle as appropriate LO 1 Evaluate the interrelationship between the different processes and functions of the organisation Justify the methodology to be used to map processes to the organisation’s goals and objectives Evaluate the output of the process and the quality gateways P M D R P M D R P M D R Feedback for LO1: LO 2 Design plans which promote goals and objectives for own area of responsibility Write objectives, which are specific, measurable, achievable, realistic and time-based to align people and other resources in an effective and efficient way Implement appropriate systems to achieve objectives in the most efficient way, on time, to budget and meeting organisational standards of quality Carry out work activities meeting the operational plan through effective monitoring and control P M D R P M D R P M D R P M D RP Feedback for LO2: LO 3 Design...
Words: 1459 - Pages: 6
...December 2011 Mini Country Report/Romania under Specific Contract for the Integration of INNO Policy TrendChart with ERAWATCH (2011-2012) Mini Country Report Thematic Report 2011 under Specific Contract for the Integration of INNO Policy TrendChart with ERAWATCH (2011-2012) December 2011 Author: Marina Ranga, Stanford University Table of Contents Preface ii Executive Summary iii 1. Innovation policy trends 1 1.1 Trends and key challenges for innovation policy 1 1.2 Innovation governance 7 1.3 Recent changes in the innovation policy mix 12 1.4 Internationalisation of innovation policies 15 1.5 Evidence on effectiveness of innovation policy 16 2. Innovation policy budgets – an overview 19 2.1 Trends in funding of innovation measures 19 2.2 Departmental and implementing agency budgets for innovation policies 2 1 2.3 Future challenges for funding of innovation policy 22 3. Thematic report: Demand-side innovation policies 23 3.1 Trends in the use of demand-side innovation policies 24 3.2 Governance challenges 30 3.3 Recent demand-side innovation policy measures 3 1 3.3.1 Sectoral specificities 3 1 3.3.2 Good practice case 3 1 Appendix A : Plan to increase the efficiency and effectiveness of RDI expenditure (Summary of provisions) 32 Appendix B : Recommendations of World Bank’s Functional Review for the reform of the Romanian RDI...
Words: 18856 - Pages: 76
...Executive Summary * The figures used for the ratio calculations were taken from the companies’ annual reports using the formulas shown in Exhibit 1. A. Global Pharmaceuticals and Medicine Manufacturing Industry (200 words) The global pharmaceutical and medicine manufacturing industry is one of the most profitable industries in the world. Currently, the industry has revenue of approximately $1.1 billion, with a forecast of growing at an annualised rate of 5.7% to $1.4 trillion by 2020. (Exhibit 4) Some of the reasons for this growth are the increasingly elderly population and rising middle class within emerging markets. Since the global population is aging, there has also been demand for products designed for age-related conditions. Lastly, the emergence of new viruses, pandemics and drug-resistant infections has prompted more research and development (R&D) in the industry, increasing the number of products in the pipeline Concentration in this industry is low, as the large pharmaceutical manufacturers only account for 15% of the market share. The most important issue faced by large pharmaceutical companies globally is the expiration of their patents, which results in the production of generic drugs by other manufacturers at lower price. The last 4 years companies have faced a series of simultaneous patent expiries, leading to severe sales losses of up to $250 billion from 2012 until today. Lastly, global trade and regulations have an impact on pricing controls...
Words: 3225 - Pages: 13
...CONTE N T S CHAI R M A N ’ S LETTE R DEAR SH AREH OL DERS FY2012 has been a good year for your Company. The key financial results were: ¥ Consolidated revenues increased by 30% to Rs. 96.7 billion in FY2012. ¥ Earnings before interest, taxes, depreciation and amortization (EBITDA)1 rose by 55% to Rs. 25.4 billion. ¥ Profit after Tax (PAT)2 grew by 45% to Rs. 15.3 billion. ¥ Diluted Earnings per Share (EPS) increased from Rs. 64.9 in FY2011 to Rs. 83.8 in FY2012. I am particularly delighted by four developments. First, your Company succeeded in yet another blockbuster generic launch in the USA under 180days marketing exclusivity. Dr. Reddy’s launched olanzapine 20 mg tablets, the generic version of the brand Zyprexa®. Olanzapine is used to treat schizophrenia and bipolar disorder. This product has added around USD 100 million to your Company’s revenues for FY2012. Second, the biosimilars business continues along its impressive growth path. In my letter to you last year, I had discussed the critical importance of developing biosimilars in the years to come. I am happy to note that your Company’s global biosimilars business grew by 45% over last year and recorded sales of USD 26 million. Today, the biosimilars portfolio of Dr. Reddy’s constitutes (i) filgrastim, (ii) peg-filgrastim, (iii) rituximab and (iv) darbepoetin alfa, which have commercial presence in 13 countries among emerging markets. These are helping to treat patients suffering from cancer — and at prices that...
Words: 128176 - Pages: 513
...internationalization of R&D activities by EU MNEs Michele Cincera , Claudio Cozza , Alexander Tübke ∗,+ * * Draft for the 4th Annual Conference of GARNET Network, IFAD, Rome, 11-13 November 2009 11.11.2009 Abstract Based on an original and recent sample representative of the largest R&D corporations in the EU, this paper aims at investigating in a quantitative way the main factors explaining: (i) the decision of firms to increase their R&D investment effort in the near future; (ii) the main drivers explaining the favorite location choice for R&D; and (iii) the impact of direct and indirect policies to support R&D activities in the EU. Main findings suggest that competitive pressures from the US are the main determinants for increasing R&D investments. Public support to R&D and proximity to other activities of the company explain the decision to locate R&D in the home country while considerations on the cost of employing researchers appear also to matter for firms preferring a location outside their home country, in particular in China and India. Key words: R&D internationalisation; drivers; R&D policies; EU large R&D corporations JEL code: O33 1. Introduction In the last decade, theoretical (Dunning and Narula, 1995; Kuemmerle, 1997) and empirical studies (among the others: Kuemmerle, 1999; Kumar, 2001; Von Zedwitz and Gassmann, 2002) on the internationalization of R&D have highlighted a shift from the so-called home-base exploiting to the home-base augmenting R&D strategies. Within...
Words: 9098 - Pages: 37
...In reviewing the financial performance of PetMed Express: The annual report of 2008 of the company describes that the company the company net income and profitability high. The revenue of the company was $10 million in 2001 and it has been reached at $108.4 million in 2005. That was a skyrocketed performance of the firm (PetMed Express (PETS), 2006). At the end of fiscal year 2008, net income of the company is $20,022,231 (PetMed Express: 2008 Annual Report, 2009). The accounting policies of the company are also critical and effective. This is the balancing loop of the organization, because it helps the management to make a balance among all the strategies and programs (PetMed Express: Our Company, 2009). Selecting this balancing feedback loop is to explain the effective strategies of the company to provide safe and quality services and products to the clients within reasonable cost. This feedback loop has been selected because it demonstrates the controlling or balancing action on the part of the organization. Reinforcing feedback loops can be describes as those loops, which amplify the feedback of the organizational output to make the inputs stronger (Galbraith, 1999). The present structure of the pharmaceutical company, in which PetMed is operating, rest on the following feedback loops. R&D investments are the main source of intellectual property and patents. Patents offer a legal barrier to entry to competition, which permits the firm to completely extract the high...
Words: 987 - Pages: 4
...Internal audit’s role in modern corporate governance Thought leadership series Risk and Advisory Services Internal audit’s role in modern corporate governance Recent events have highlighted the critical role of boards of directors in promoting good corporate governance. In particular, boards are being charged with ultimate responsibility for the effectiveness of their organisations’ internal control systems. An effective internal audit function plays a key role in assisting the board to discharge its governance responsibilities. Yet how does the board – and its audit committee – satisfy itself that internal audit is functioning effectively and efficiently? The board’s responsibility for internal controls Through working with a broad range of organisations in Hong Kong and internationally, KPMG has identified a number of best practices in relation to the role played by the board audit and/or risk management committees. s Recent events have highlighted the critical role of boards of directors in s s s s s s s Assessing the scope and effectiveness of the systems established by management to identify, assess, manage and monitor the various risks arising from the organisation’s activities. Ensuring senior management establishes and maintains adequate and effective internal controls. Satisfying itself that appropriate controls are in place for monitoring compliance with laws, regulations, supervisory requirements and relevant internal policies....
Words: 2896 - Pages: 12
...expected to witness phenomenal growth in the coming years. Increasing fuel costs, rise in pollution level and increasing government support will boost the adoption of electric vehicles in India. The report begins with an overview of the major macro economic indicators which highlights the present economic scenario prevalent in India. The introduction section provides the definition of an electric vehicle with its major components. It also mentions the various types of electric vehicles based on technology, such as, battery electric vehicles, plug in hybrid electric vehicles, hybrid electric vehicles and fuel cell electric vehicles. This section further depicts the transition path of electric vehicle market over the years, highlighting the reasons for shift towards electric mobility in the future. This is followed by the market overview section which provides an insight into the overall electric vehicle market in India. The market size and forecasted growth along with the market segments and their respective shares have been mentioned in the report. This section further includes a cost comparison between electric vehicles and conventional internal combustion engine vehicles across the supply chain and manufacturing process. Moving along, electric vehicle market segments section in the report elaborates the three basic market segments, electric four wheelers, two wheelers and three wheelers, wherein it lists their respective market size and forecasted growth. It also reveals the consumer...
Words: 913 - Pages: 4
...and G3.1 Update – Comparison Sheet Principles for Defining Report Content KEY TO UPDATES STAKEHOLDER INCLUSIVENESS Principles for Ensuring Report Quality The report should reflect positive and negative aspects of the organization’s performance to enable a reasoned assessment of overall performance. BAL ANCE COMPAR ABILIT Y TIMELINESS Reporting occurs on a regular schedule and information is available in time for stakeholders to make informed decisions. CL ARIT Y Information should be made available in a manner that is understandable and accessible to stakeholders using the report. RELIABILIT Y XX01 Indicates content introduced in G3.1 Refer to the G3.1 Guidelines and Indicator Protocols for full details or to the Comparison Tables for an at-a -glance view of the extent of changes applied to G3.1 The reporting organization should identify its stakeholders and explain in the report how it has responded to their reasonable expectations and interests. SUSTAINABILIT Y CONTEX T MATERIALIT Y The information in a report should cover topics and Indicators that: • reflect the organization’s significant economic, environmental, and social impacts, or that • would substantively influence the assessments and decisions of stakeholders. The report should present the organization’s performance in the wider context of sustainability. Coverage of the material topics and Indicators and definition of the report boundary should be sufficient to reflect significant economic...
Words: 5252 - Pages: 22
...Inventories IFRS and GAAP adopts different rules Inventory for using lower of the market method. Under GAAP, an entity should first pick the medium number amongst market ceiling (net realizable value, market floor (net realizable value minus normal profit), and replacement cost. Then compare that medium number with the cost of the inventory. Under IFRS, one only needs to compare the market ceiling value with the cost of inventory. According to the 2013, AT&T includes its inventory in “other current assets” on the balance sheet, which are valued at the lower of cost or market. Telecom Italia lists its inventory as a line item under current assets. It also adopts lower of the cost or market to evaluate its inventories. It is a one-step test by simply comparing the market ceiling value and the cost of inventory. Telecom Italia wrote down by 4 million based on the adjustment to estimated realizable value of its fixed asset. Leases The guidance for distinguish operating and financial leases are similar under IFRS & GAAP. GAAP has a more detailed guidance for capital lease. They have dissimilarities for rules over sale-lease back. Telecom Italia should refer to IAS 17 for its lease reporting, while AT&T should refer to ASC 840 for its financial reporting. Capital lease is “finance lease” under IFRS. Compared to Telecom Italia, the capital lease of AT&T is not significant because of the strict rule for a lessor to claim a capital asset under GAAP. The accounting...
Words: 973 - Pages: 4
...reporting R&D expenditure, with a specific emphasis to pharmaceutical industry. This essay challenges the current dogma of considering R&D as an expanse and also provides some insights into overcoming these challenges. INTRODUCTION Accounting is an art and science of communicating the financial information of the organizations to its managers, employees, investors, creditors etc. There are numerous rules and principals set to report and record these financial transactions, mainly govern by Financial Accounting Standards Board (FASB) in USA known as Generally Accepted Accounting Principles (GAAP) and International Accounting Standards Board (IASB) for international standards known as International Financial Reporting Standards (IFRS). Unlike other industrial sectors, Research and Development (R&D) is the key strength and major financial obligation of pharmaceutical companies. Depending on the size and growth stage, pharmaceutical companies spend 30-40% of their total revenue in R&D. Due to robust healthcare spending pharmaceutical industrial growth is rapidly sprouting worldwide. According to the recent IMS world review and McKinsey Global Institute Report (1), USA remains on top with 444 billion USD projected pharmaceutical markets in year 2015. Therefore, it is imperative to develop logically standardized GAPP and IFRS principals and processes for reporting R&D in financial statements. The disparities among current accounting practices related to R&D reporting...
Words: 339 - Pages: 2
